Clinical Trials
55 results for Prostate Cancer
1-50 of 55 Next
Prospective Evaluation of CyberKnife® as Monotherapy or Boost Stereotactic Body Radiotherapy for Intermediate or High Risk Localized Prostate Cancer
- Condition: Prostate Adenocarcinoma
- Intervention: Radiation: CyberKnife, Other: Androgen Deprivation Therapy (ADT), Radiation: Intensity Modulated radiation therapy (IMRT)
- Study ID: NCT01985828
A Pilot Study of Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (13C) to Detect High Grade Localized Prostate Cancer
- Condition: Prostate Cancer
- Intervention: Drug: Pyruvate (13C)
- Study ID: NCT02526368
The UCLA ASCAP Project is an Observational, Longitudinal, and Open-ended Study Aimed at Establishing a Structured Program of Non-interventional Follow-up for Localized Prostate Cancer.
- Condition: Prostate Cancer
- Intervention: Other: Active surveillance
- Study ID: NCT00949819
Prospective Evaluation of CyberKnife Stereotactic Body Radiotherapy for Localized Prostate Cancer: Risk Stratified Monotherapy Versus Boost
- Condition: Prostate Cancer
- Intervention:
- Study ID: NCT02016248
Perioperative Pelvic Floor Muscle Training May Improve Recovery of Continence in Men With Localized Prostate Cancer Undergoing Robot-Assisted Radical Prostatectomy
- Condition: Prostate Cancer, Urinary Incontinence, Pelvic Floor Physical Therapy
- Intervention:
- Study ID: NCT02558946
Primary Radical Prostatectomy Versus Primary Radiotherapy for Locally Advanced Prostate Cancer: an Open Randomized Clinical Trial
- Condition: Prostatic Neoplasms
- Intervention: Procedure: Prostatectomy/Surgery, Other: Radiotherapy with adjuvant androgen deprivation therapy
- Study ID: NCT02102477
Focal Low Dose Rate ( LDR) Brachytherapy: Hemi-ablative Treatment With LDR for Patients With Low and Low-tier Intermediate Risk Prostate Cancer
- Condition: Prostate Cancer
- Intervention: Radiation: Transperineal template guided mapping biopsy, multiparametric MRI, Hemiablative Focal Brachytherapy
- Study ID: NCT02643511
Safety and Early Efficacy of Radical Prostatectomy for Newly Diagnosed Very High Risk Locally Advanced and Oligometastatic Prostate Cancer - a Prospective Single Center Phase I/II Study
- Condition: Locally Advanced and Metastatic Prostate Cancer
- Intervention: Procedure: Radical prostatectomy
- Study ID: NCT02971358
Phase III Study of Image Guided Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Adenocarcinoma of the Prostate
- Condition: Prostate Cancer
- Intervention: Radiation: Radiation, Drug: Androgen Suppression Therapy
- Study ID: NCT01492972
A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin in Reducing Progression Among Men on Expectant Management for Low Risk Prostate Cancer: The MAST (Metformin Active Surveillance Trial) Study
- Condition: Prostate Cancer
- Intervention: Drug: Metformin, Drug: Placebo
- Study ID: NCT01864096
Local Treatment With Radical Prostatectomy (RP) for Newly-diagnosed Metastatic Prostate Cancer (mPCa).
- Condition: Prostatic Neoplasms, Neoplasm Metastasis
- Intervention:
- Study ID: NCT02138721
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients
- Condition: Breast Cancer, Bladder Cancer, Kidney Cancer, Colon Cancer, Prostate Cancer, Lung Cancer, Ovarian Cancer
- Intervention: Genetic: PCR/PCR/LDR Strategy
- Study ID: NCT00579514
Collection of Blood From Patients With Prostate Cancer
- Condition: Prostatic Neoplasms
- Study ID: NCT00923221
Canary Prostate Active Surveillance Study
- Condition: Prostatic Neoplasms
- Study ID: NCT00756665
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- Condition: Prostate Cancer
- Intervention: Drug: [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone
- Study ID: NCT00588185
A Pilot Study of High Dose Rate Brachytherapy in The Radiation Oncology Branch
- Condition: Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Prostate Cancer, Biliary Cancer
- Intervention: Radiation: Brachytherapy
- Study ID: NCT00924027
Hereditary Leiomyomatosis Renal Cell Cancer (HLRCC): Identification of the Disease Gene and Characterization of the Predisposition to Renal Cancer
- Condition: Renal Tumor Histology, Cutaneous Leiomyomatosis, Kidney Cancer
- Study ID: NCT00050752
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
- Condition: Malignant Neoplasms, Hereditary Neoplastic Syndromes, Kidney Cancer, Renal Cancer
- Study ID: NCT00026884
A Phase III Randomized Trial of MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial
- Condition: Prostate Cancer, Prostate Adenocarcinoma
- Intervention: Radiation: Standard Salvage Radiation Treatment (SSRT), Radiation: Mapped Tumor Salvage RT (MTSRT), Behavioral: Expanded Prostate Cancer Index Composite-SF12, Behavioral: Memory Anxiety Scale for Prostate Cancer patients, Behavioral: International Prostate Symptom Score (IPSS)
- Study ID: NCT01411345
Postoperative or Salvage Radiotherapy for Node Negative Prostate Cancer Following Radical Prostatectomy
- Condition: Prostate Cancer
- Intervention: Radiation: IMRT to 45 Gy; prostate bed proton boost of 21.6 CGE, Radiation: Proton (prostate bed) to 70.2 CGE, Radiation: IMRT to 45 Gy; proton boost to prostate bed to 25.2 CGE, Radiation: Proton to 66.6 CGE
- Study ID: NCT00969111
A Randomized Trial of Modifications to Radical Prostatectomy
- Condition: Prostate Cancer
- Intervention: Procedure: Lymph node template, Procedure: Transverse versus vertical closure, Drug: antibiotic prophylaxis
- Study ID: NCT01407263
Collection of Blood From Patients With Cancer for Analysis of Genetic Differences in Drug Disposition
- Condition: Prostate Cancer, Breast Cancer, Lung Cancer, Ovarian Cancer, Lymphoma
- Study ID: NCT01441089
Biospecimen Acquisition From Human Subjects
- Condition: Prostate Cancer, Breast Cancer, Colon Cancer, Lung Cancer, Liver Cancer
- Intervention:
- Study ID: NCT00034216
Carbon Ion Radiotherapy for the Treatment of Localized Prostate Cancer
- Condition: Prostate Carcinoma
- Intervention:
- Study ID: NCT02739659
Phase I/II Study of PROSTVAC in Combination With Nivolumab and / or Ipilimumab in Men With Prostate Cancer
- Condition: Prostate Cancer
- Intervention: Biological: PROSTVAC-V/F, Drug: Nivolumab, Drug: Ipilimumab
- Study ID: NCT02933255
HDR Monotherapy for Prostate Cancer: A Feasibility Study of Focal Radiotherapy Yields
- Condition: Prostate Cancer
- Intervention: Radiation: targeted focal HDR brachytherapy, Radiation: Whole-gland HDR Brachytherapy
- Study ID: NCT02918253
Phase II Study: [18F]DCFPyL PET/MRI for Personalizing Prostate Cancer Subclinical Metastatic Ablative MR-guided Radiotherapy (MRgRT)
- Condition: Post Prostatectomy
- Intervention: Diagnostic Test: [18F]DCFPyL PET/MRI scan, Radiation: Stereotactic Ablative Radiotherapy
- Study ID: NCT03160794
Prostate Cancer Outcomes: An International Registry to Improve Outcomes in Men With Advanced Prostate Cancer (IRONMAN)
- Condition: Prostate Cancer
- Intervention: Other: Standard of Care
- Study ID: NCT03151629
Diagnosing Clinically Significant Prostate Cancer in African American and White Men Phase II, Randomized Clinical Trial, Multi-center, MR-Guided vs. 12-core Systematic Random Biopsy, Localized Prostate Cancer
- Condition: Health Status Unknown, PSA Progression
- Intervention: Procedure: Biopsy of Prostate, Other: Laboratory Biomarker Analysis, Diagnostic Test: Magnetic Resonance Imaging, Diagnostic Test: MRI Ultrasound Fusion Guided Biopsy
- Study ID: NCT03234556
Cognitive Effects of Androgen Receptor (AR) Directed Therapies for Advanced Prostate Cancer
- Condition: Castration-Resistant Prostatic Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer, Hormone-Refractory Prostate Cancer
- Intervention: Biological: GnRH agonist/antagonist, Drug: Prednisone, Drug: Abiraterone Acetate, Drug: Enzalutamide
- Study ID: NCT03016741
PHASE I STUDY OF PSMA-TGFβRDN CAR MODIFIED T CELLS IN PATIENTS WITH ADVANCED CASTRATE RESISTANT PROSTATE CANCER
- Condition: Prostate Cancer
- Intervention:
- Study ID: NCT03089203
Phase II Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations (TRIUMPH)
- Condition: Prostate Cancer Metastatic
- Intervention: Drug: Rucaparib
- Study ID: NCT03413995
Cystoprostatectomy Versus Radiotherapy Combined With Androgen Deprivation Therapy for the Treatment of Clinical T4 Prostate Cancer With Bladder Invasion: a Multicentre, Prospective, Open, Randomized Clinical Trial
- Condition: Prostate Cancer
- Intervention: Procedure: Cystoprostatectomy, Radiation: external beam radiotherapy
- Study ID: NCT03482089
Bone Response After Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients With Hormone Sensitive Metastatic Bone Disease: a Prospective, Phase II, Randomized, Multicenter Study
- Condition: Prostate Cancer, Bone Metastases
- Intervention: Drug: Zoledronic Acid, Drug: Enzalutamide
- Study ID: NCT03336983
A Phase 2 Trial of Radium Ra 223 Dichloride in Combination With Androgen Deprivation Therapy and Stereotactic Body Radiation Therapy for Patients With Oligometastatic Castration Sensitive Prostate Cancer
- Condition: Prostate Adenocarcinoma
- Intervention: Drug: Leuprolide Acetate, Drug: Goserelin Acetate, Radiation: Stereotactic Body Radiation Therapy, Radiation: Radium Ra 223 Dichloride, Other: Laboratory Biomarker Analysis
- Study ID: NCT03361735
Quality of Life in Patients With Clinically Localized Prostate Cancer Treated With Stereotactic Body Radiation Therapy (SBRT)
- Condition: Prostate Cancer, Localized Malignant Neoplasm
- Intervention: Radiation: Stereotactic Body Radiation Therapy (SBRT)
- Study ID: NCT01766492
Phase II Study of Neoadjuvant Pembrolizumab Plus Intensive Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer
- Condition: Prostate Cancer
- Intervention: Drug: Pembrolizumab, Drug: Enzalutamide
- Study ID: NCT03753243
Phase 2, Multicenter, Prospective Cohort Study, Estimating the Efficacy of Focused HIFU Therapy in Patients With Localized Intermediate Risk Prostate Cancer
- Condition: Prostate Cancer
- Intervention: Procedure: treatment with focal HIFU, Biological: PSA dosage, Device: MRI, Other: Questionnaires, Procedure: Prostatic biopsies, Biological: blood test, Biological: urine test
- Study ID: NCT03568188
A Randomized Pilot Study Comparing High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy in Localized Prostate Cancer
- Condition: Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
- Intervention: Radiation: High-Dose Rate Brachytherapy, Other: Quality-of-Life Assessment, Other: Questionnaire Administration, Procedure: Stereotactic Ablative Radiotherapy
- Study ID: NCT04253483
Hypofractionated Radiosurgery for Localised Prostate Cancer
- Condition: Prostate Cancer
- Intervention: Radiation: Hypofractionated Radiosurgery
- Study ID: NCT03795337
SAABR: Single-Arm Phase II Study of Abiraterone Acetate + Atezolizumab + Lupron and Stereotactic Body Radiotherapy (SBRT) to the Prostate in Men With Newly Diagnosed Hormone-sensitive Metastatic Prostate Cancer
- Condition: Metastatic Prostate Cancer
- Intervention: Drug: Atezolizumab, Drug: Abiraterone, Drug: Prednisone, Drug: Lupron, Radiation: Stereotactic Body Radiotherapy (SBRT)
- Study ID: NCT04262154
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
- Condition: Prostatic Neoplasms
- Intervention: Drug: Apalutamide, Drug: Androgen Deprivation Therapy (ADT), Drug: Placebo
- Study ID: NCT03767244
Phase 3, Multicenter, Randomized Study, Evaluating the Efficacy and Tolerability of Focused HIFU Therapy Compared to Active Surveillance in Patients With Significant Low Risk Prostate Cancer
- Condition: Prostate Cancer
- Intervention: Procedure: treatment with focal HIFU, Biological: PSA dosage, Device: MRI, Other: Questionnaires, Procedure: Prostatic biopsies
- Study ID: NCT03531099
A Randomized Phase II Trial to Evaluate the Antitumor Activity of Enzalutamide and Talazoparib (PF-06944076) for the Treatment of Metastatic Hormone-naïve Prostate Cancer
- Condition: Metastatic Prostate Cancer
- Study ID: NCT04332744
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Re
- Condition: Metastatic Castrate Sensitive Prostate Cancer
- Study ID: NCT04497844
Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients - a GETUG-AFU Phase III Randomized Controlled Trial
- Condition: Oligometastatic Hormone Sensitive Prostate Cancer
- Study ID: NCT04115007
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, With an Observational Fol
- Condition: Prostatic Neoplasms
- Study ID: NCT04557059
Phase 4 Study of Exploring Circulating Tumor DNA (ctDNA) of Metastatic Castration-sensitive Prostate Cancer (mCSPC) Patients Receiving Apalutamide in Japan
- Condition: Metastatic Castration-sensitive Prostate Cancer
- Study ID: NCT04601441
TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
- Condition: Prostate Cancer
- Study ID: NCT04821622
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
- Condition: Prostatic Neoplasms
- Study ID: NCT04720157